April 26, 2024
A5481092 PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB(IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS